Paper41357313
SCOPING: A Multidisciplinary Treatment Protocol for Neovascular Glaucoma with Completely Open or Partially Open Angles.
Mokhashi N and 7 others. Clin Ophthalmol, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. SCOPING: A Multidisciplinary Treatment Protocol for Neovascular Glaucoma with Completely Open or Partially Open Angles. Papers, record 41357313. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41357313
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SCOPING: A Multidisciplinary Treatment Protocol for Neovascular Glaucoma with Completely Open or Partially Open Angles.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References12
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23907153 | Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography. | JAMA Ophthalmol | 2013 | https://conductscience.org/library/papers/23907153 | PubMed |
| 2 | 37929013 | Cyclophotocoagulation in Neovascular Glaucoma with Near-Total Synechial Angle Closure. | Case Rep Ophthalmol Med | 2023 | https://conductscience.org/library/papers/37929013 | PubMed |
| 3 | 35935916 | Neovascular Glaucoma from Ocular Ischemic Syndrome Treated with Serial Monthly Intravitreal Bevacizumab and Panretinal Photocoagulation: A Case Report. | Case Rep Ophthalmol Med | 2022 | https://conductscience.org/library/papers/35935916 | PubMed |
| 4 | 18440643 | Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. | Ophthalmology | 2008 | https://conductscience.org/library/papers/18440643 | PubMed |
| 5 | 30587917 | Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab. | Clin Ophthalmol | 2019 | https://conductscience.org/library/papers/30587917 | PubMed |
| 6 | 3692707 | Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. | Int Ophthalmol Clin | 1987 | https://conductscience.org/library/papers/3692707 | PubMed |
| 7 | 35031284 | Improving Outcomes in Neovascular Glaucoma. | Ophthalmol Glaucoma | 2022 | https://conductscience.org/library/papers/35031284 | PubMed |
| 8 | 28992424 | Long-Term Outcome of Intravitreal Bevacizumab Followed by Ahmed Valve Implantation in the Management of Neovascular Glaucoma. | Semin Ophthalmol | 2018 | https://conductscience.org/library/papers/28992424 | PubMed |
| 9 | 19373696 | Neovascular glaucoma: etiology, diagnosis and prognosis. | Semin Ophthalmol | 2009 | https://conductscience.org/library/papers/19373696 | PubMed |
| 10 | 34487226 | Gonioscopy-assisted transluminal trabeculotomy for chronic angle-closure glaucoma: preliminary results. | Graefes Arch Clin Exp Ophthalmol | 2022 | https://conductscience.org/library/papers/34487226 | PubMed |
| 11 | 19826393 | Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. | J Glaucoma | 2009 | https://conductscience.org/library/papers/19826393 | PubMed |
| 12 | 36051187 | Gonioscopy-assisted transluminal trabeculotomy in neovascular glaucoma: Salvaging the conventional outflow pathway. | Am J Ophthalmol Case Rep | 2022 | https://conductscience.org/library/papers/36051187 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42254353 | Neovascular glaucoma: pathophysiology, diagnosis, and contemporary management. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42254353 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41357313
GET https://conductscience.org/api/papers/v1/41357313/authors